// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























13968 Abstracts

Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

David S. Ziegler - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

PEG-asparaginase

A Window Study of Acalabrutinib Plus Rituximab Followed By R-Dhaox (rituximab, dexamethasone, cytarabine, oxaliplatin) and Autologous Stem Cell Transplant (ASCT) in Fit Mantle Cell Lymphoma (MCL): The Australasian Leukaemia & Lymphoma Group (ALLG) NHL33 Wamm Trial

Eliza Hawkes - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

Dexamethasone

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

Matko Kalac - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

Azacitidine

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Amer M. Zeidan - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic myelomonocytic leukemia

Azacitidine

Assessing the Immune Tumour Microenvironment (iTME) Using Multiplex Immunoflourescence Histochemistry (mIHC) Demonstrates Close Proximity of Cytotoxic T-Cells to Plasma Cells (PC) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Slavisa Ninkovic - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Inferior Outcomes for Multiple Myeloma (MM) Patients (pts) Harbouring t(11;14) and the Promise of Venetoclax, Real-World Australian Retrospective

Kenneth JC Lim - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Venetoclax

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Khai Li Chai - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Vaishali Sanchorawala - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

AL Amyloidosis

Dexamethasone

Optimizing Viable CD34 + Enumeration in Cryopreserved HPC Samples for Implementation of an External QA Program - Relevance to the Current Pandemic

Scott J Ragg - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Recurrent CMV Viremia Portends Poor Prognosis and Results in Significant Resource Utilization in Patients with Poor Graft Function Post Allogeneic Stem Cell Transplantation

Ashvind Anand Prabahran - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

ST100

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Brian O'Mahony - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

A Minority of Women of Child Bearing Potential Are Tested for Pregnancy before Chemoimmunotherapy: An Australian Cancer Centre Experience

Verity L Chadwick - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Infertility

Rituximab

Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey

Zack Pemberton-Whiteley - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

L-Tyrosine

Assisted Reproductive Technology Required to Achieve High Conception Rates, Despite a Low Incidence of Hypogonadotrophic Hypogonadism in Thalassemia and Sickle Cell Disease Patients

Jacinta Perram - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Results of the International Survey on Adherence with Anticoagulation in Children, Adolescents and Young Adults

Courtney D Thornburg - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Hydroxyzine

KLF1 Acts As a Pioneer Transcription Factor Via SMARCA4 to Open Chromatin and Facilitate Redeployment of an Enhancer Complex Containing GATA1 and SCL

Graham William Magor - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Anemia, congenital dyserythropoietic, 4

Afimoxifene

A Putative Erythroid Synapse Linking Developing Erythroblasts and Macrophages in Erythroblastic Islands

Chanukya K Colonne - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

Interferon

De Novo Germline DHX38 Variant Associated with Alternative Splicing of Multiple Transcripts in Iron-Related Pathways in a Patient with Atypical Congenital Dyserythropoietic Anemia with Ring Sideroblasts

Aikaterini Voulgaridou - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Diamond-Blackfan anemia

N/A

Novel Immediate Direct Targets of EPO Signalling in Human Erythropoiesis

Charlene Lam - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Erythropoietin

Randomised Controlled Trial of Intravenous Iron (ferric carboxymaltose) for Second Trimester Anaemia in Malawian Pregnant Women (REVAMP)

Sant-Rayn Pasricha - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Anemia

Ferric carboxymaltose

Copyright © 2026. QuantiNova All rights reserved